Jeff Yass’s Oramed Pharmaceuticals ORMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $107K | Sell |
22,300
-113,918
| -84% | -$453K | ﹤0.01% | 12454 |
|
|
2026
Q1 | $463K | Buy |
136,218
+110,234
| +424% | +$374K | ﹤0.01% | 9875 |
|
|
2025
Q4 | $74.1K | Sell |
25,984
-10,841
| -29% | -$28K | ﹤0.01% | 11601 |
|
|
2025
Q3 | $97.2K | Sell |
36,825
-11,603
| -24% | -$25.6K | ﹤0.01% | 11579 |
|
|
2025
Q2 | $109K | Sell |
48,428
-51,768
| -52% | -$114K | ﹤0.01% | 11743 |
|
|
2025
Q1 | $214K | Buy |
100,196
+9,169
| +10% | +$21.2K | ﹤0.01% | 10800 |
|
|
2024
Q4 | $220K | Sell |
91,027
-43,346
| -32% | -$103K | ﹤0.01% | 10506 |
|
|
2024
Q3 | $328K | Buy |
134,373
+8,545
| +7% | +$20.8K | ﹤0.01% | 9408 |
|
|
2024
Q2 | $323K | Sell |
125,828
-218,610
| -63% | -$520K | ﹤0.01% | 9283 |
|
|
2024
Q1 | $1.01M | Buy |
344,438
+298,522
| +650% | +$835K | ﹤0.01% | 6909 |
|
|
2023
Q4 | $106K | Buy |
45,916
+32,848
| +251% | +$70.2K | ﹤0.01% | 11281 |
|
|
2023
Q3 | $34.1K | Sell |
13,068
-74,435
| -85% | -$234K | ﹤0.01% | 11437 |
|
|
2023
Q2 | $313K | Buy |
87,503
+73,314
| +517% | +$235K | ﹤0.01% | 9344 |
|
|
2023
Q1 | $30.9K | Sell |
14,189
-171,417
| -92% | -$545K | ﹤0.01% | 11898 |
|
|
2022
Q4 | $2.23M | Buy |
185,606
+14,269
| +8% | +$111K | ﹤0.01% | 4502 |
|
|
2022
Q3 | $1.11M | Buy |
171,337
+64,699
| +61% | +$524K | ﹤0.01% | 6364 |
|
|
2022
Q2 | $488K | Buy |
106,638
+28,653
| +37% | +$153K | ﹤0.01% | 8324 |
|
|
2022
Q1 | $675K | Sell |
77,985
-38,423
| -33% | -$394K | ﹤0.01% | 8178 |
|
|
2021
Q4 | $1.66M | Buy |
116,408
+99,976
| +608% | +$2.09M | ﹤0.01% | 5959 |
|
|
2021
Q3 | $361K | Buy |
16,432
+4,430
| +37% | +$75.5K | ﹤0.01% | 10167 |
|
|
2021
Q2 | $161K | Sell |
12,002
-56,303
| -82% | -$644K | ﹤0.01% | 11800 |
|
|
2021
Q1 | $694K | Buy |
+68,305
| New | +$561K | ﹤0.01% | 8676 |
|
|
2020
Q1 | – | Sell |
-13,628
| Closed | -$59.7K | – | 10699 |
|
|
2019
Q4 | $70K | Sell |
13,628
-1,176
| -8% | -$4.41K | ﹤0.01% | 9255 |
|
|
2019
Q3 | $47K | Buy |
+14,804
| New | +$49.3K | ﹤0.01% | 9793 |
|
|
2018
Q1 | – | Sell |
-18,474
| Closed | -$166K | – | 9932 |
|
|
2017
Q4 | $166K | Sell |
18,474
-288
| -2% | -$2.75K | ﹤0.01% | 8422 |
|
|
2017
Q3 | $185K | Buy |
+18,762
| New | +$162K | ﹤0.01% | 8073 |
|
|
2015
Q4 | – | Sell |
-10,972
| Closed | -$83.2K | – | 9802 |
|
|
2015
Q3 | $60K | Buy |
+10,972
| New | +$69K | ﹤0.01% | 9325 |
|
|
2015
Q1 | – | Sell |
-12,468
| Closed | -$60.2K | – | 9785 |
|
|
2014
Q4 | $57K | Buy |
12,468
+2,329
| +23% | +$15.3K | ﹤0.01% | 9342 |
|
|
2014
Q3 | $82K | Sell |
10,139
-18,440
| -65% | -$164K | ﹤0.01% | 9128 |
|
|
2014
Q2 | $275K | Buy |
28,579
+4,298
| +18% | +$43.9K | ﹤0.01% | 8530 |
|
|
2014
Q1 | $282K | Buy |
+24,281
| New | +$410K | ﹤0.01% | 7679 |
|
Other funds holding ORMP
AF
GIA
M
BCM
BFM
Jeff Yass's ORMP Position: Q2 2026 in Review
Jeff Yass reduced its Oramed Pharmaceuticals (ORMP) stake by 84% in Q2 2026, selling an estimated $453K and leaving 22,300 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #12454.
Jeff Yass first reported a position in ORMP in Q1 2014 and has held it in 31 quarters since. The position peaked at $2.23M in Q4 2022. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.
- Jeff Yass held 22,300 shares of Oramed Pharmaceuticals worth $107K as of Q2 2026.
- Jeff Yass sold 113,918 Oramed Pharmaceuticals shares in Q2 2026, an estimated $453K.
- Oramed Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12454 holding.
- Jeff Yass first reported a position in Oramed Pharmaceuticals in Q1 2014 and has held it in 31 quarters since.
- Jeff Yass's Oramed Pharmaceuticals position peaked at $2.23M in Q4 2022.
- 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.